Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled date : 2021 - 11 - 09 save search
Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies
Published: 2021-11-09 (Crawled : 20:00) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: -1.25%
H: 0.63%
C: -5.91%
cancer license t-cell
Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer
Published: 2021-11-09 (Crawled : 19:00) - biospace.com/
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 5.26%
H: 0.0%
C: -25.6%
results cancer breast cancer metastatic breast cancer
Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting
Published: 2021-11-09 (Crawled : 19:00) - biospace.com/
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: 1.47%
H: 2.91%
C: -2.42%
immunotherapy phase 1 renal positive therapy cancer phase 1b trial phase 2b cell carcinoma
Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Published: 2021-11-09 (Crawled : 19:00) - biospace.com/
IMCR | $55.71 1.77% 1.74% 450K
|
Manufacturing
| Email alert
Add to watchlist
immunotherapy therapy cancer
aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting
Published: 2021-11-09 (Crawled : 17:00) - biospace.com/
LIFE | $1.6 -1.23% -1.25% 160K
|
Health Technology
|
| O: -0.47%
H: 2.73%
C: 2.02%
immunotherapy therapy cancer antibody research
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cancer Specialist During 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Published: 2021-11-09 (Crawled : 15:15) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M
|
Health Technology
|
| O: -0.96%
H: 1.24%
C: -4.76%
immunotherapy therapy cancer conference
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
Published: 2021-11-09 (Crawled : 15:15) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -0.69%
H: 0.83%
C: -1.02%
lung cancer cancer phase 3 trial enroll
Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting
Published: 2021-11-09 (Crawled : 14:15) - biospace.com/
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: -2.04%
H: 0.0%
C: 0.0%
immunotherapy therapy cancer arcus car-t t-cell
Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
Published: 2021-11-09 (Crawled : 14:00) - biospace.com/
IMV | $0.8225 -2.74% 45K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -4.32%
cancer ovarian cancer
Study Shows Biocept’s Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations
Published: 2021-11-09 (Crawled : 14:00) - biospace.com/
BIOC | $0.4349 -10.32% 750K
|
Health Services
|
| O: -1.28%
H: 1.3%
C: 1.04%
cancer technology rare
Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2021-11-09 (Crawled : 14:00) - globenewswire.com
IOVA | News M | $11.32 -3.41% -3.53% 5.3M
|
Health Technology
|
| O: -0.36%
H: 4.65%
C: -0.64%
immunotherapy solid tumors therapy cancer iot
Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting
Published: 2021-11-09 (Crawled : 13:15) - prnewswire.com
PSTX | $2.02 1.0% 0.99% 640K
|
Health Technology
|
| O: -1.96%
H: 0.0%
C: 0.0%
immunotherapy therapy car-t cancer preclinical pre-clinical
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.